International Board of Directors

2020 - 2021 ISPE International Board of Directors Election

The ISPE International Board of Directors 2020 Election is closed and the 2020 - 2021 ISPE International Board of Directors have been elected. 

Meet the 2020 - 2021 ISPE International Board of Directors

The leadership transition between the 2019 - 2020 Board and the 2020 - 2021 Board will take place during the 2020 ISPE Annual Meeting & Expo on Thursday, 5 November.


Officers

Joanne R. Barrick, RPh
Advisor, Global Validation
Eli Lilly and Company
Chair
Joerg Zimmermann
Vice President, Vetter Development Service, External Affairs
Vetter Pharma-Fertigung GmbH & Co.
Vice Chair
Michael L. Rutherford
Executive Director, Computer Systems Quality & Data Integrity
Syneos Health
Treasurer
Scott W. Billman
Global Head of Engineering
Biogen
Secretary
Frances M. Zipp
President & CEO
Lachman Consultant Services, Inc.
Past Chair

Directors Elected to a Second Term

Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Chris Chen, PhD
CEO
WuXi Biologics (Shanghai) Co., Ltd.

New Directors

Nina S. Cauchon, PhD
Director Regulatory Affairs - CMC
Amgen Inc.
Teresa Minero
Founder & CEO
LifeBee - Digitalizing Life Sciences
Hirofumi Suzuki, PhD
Senior Regulatory CMC Adviser
Bayer Yakuhin Ltd
David Doleski
Compliance Head for Biologics Quality Operations
Sanofi
Board Appointed Director

Continuing Board Members

Ylva Ek
Chief Quality Officer (CQO)
KeyPlants AB
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals
Stephen C. Mahoney, JD
Senior Director, Global Quality & Compliance
Genentech, A Member of the Roche Group
Alice Redmond, PhD
Vice President, European Operations
CAI

Ex Officio

John Clarke
Operations Lead
Pfizer
Board Young Professionals Representative (Non-voting)

Board Members Completing Their Service

The following individuals will complete their Board service and will officially end their term at the 2020 ISPE Annual Meeting & Expo. ISPE thanks these individuals for their dedication and commitment to the organization.

James A. Breen, Jr., PE
Vice President, Lead Biologics Expansion
Janssen Pharmaceuticals
Chair 2018 - 2019 & Past Chair 2019 - 2020
Gunter Baumgartner
Senior Vice President, Head of Global Engineering
Takeda Pharmaceuticals International AG
Christine M. V. Moore, PhD
Global Head and Executive Director, GRACS CMC Policy
Merck & Co, Inc.
LeAnna M. Pearson
Sr. Project Manager
PharmEng Technology
Caroline Rocks, CEng
Senior Principal Engineer
AbbVie, Inc.

2019 - 2020 ISPE International Board of Directors

The Board is responsible for the governance and strategic direction of the Society. The following pharmaceutical industry leaders have been elected to positions on the 2019–2020 ISPE International Board of Directors:

Officers

Frances M. Zipp
President & CEO
Lachman Consultant Services, Inc.
Chair
Contact
Term: 2019 – 2020
Joanne R. Barrick, RPh
Advisor, Global Validation
Eli Lilly and Company
Treasurer 
Contact
Term: 2019 – 2020
Joerg Zimmermann
Vice President, Vetter Development Service, External Affairs
Vetter Pharma-Fertigung GmbH & Co.
Secretary
Contact
Term: 2019 – 2020
James A. Breen, Jr., PE
Vice President, Lead Biologics Expansion
Janssen Pharmaceuticals
Past Chair
Contact
Term: 2019 – 2020
Thomas B. Hartman
President and CEO
ISPE
Contact
 

Directors

Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Contact
Term: 2018 – 2020 (Second term)
Gunter Baumgartner
Senior Vice President, Head of Global Engineering
Takeda Pharmaceuticals International AG
Contact
Term: 2018 – 2020 (Second term)
Scott W. Billman
Global Head of Engineering
Biogen
Contact
Term: 2019 – 2020 (First term)
Chris Chen, PhD
CEO
WuXi Biologics (Shanghai) Co., Ltd.
Contact
Term: 2018 – 2020 (Appointed)
Ylva Ek
Chief Quality Officer (CQO)
KeyPlants AB
Contact
Term: 2019 – 2020 (First term)
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals
Contact
Term: 2019 – 2020 (First term)
Stephen C. Mahoney, JD
Senior Director, Global Quality & Compliance
Genentech, A Member of the Roche Group
Contact
Term: 2019 – 2020 (First term)
Christine M. V. Moore, PhD
Global Head and Executive Director, GRACS CMC Policy
Merck & Co, Inc.
Contact
Term: 2018 – 2020 (Second term)
Alice Redmond, PhD
Vice President, European Operations
CAI
Contact
Term: 2017 – 2020 (Third term)
Caroline Rocks, CEng
Senior Principal Engineer
AbbVie, Inc.
Contact
Term: 2018 – 2020 (Second term)

Ex Officio

LeAnna M. Pearson
Sr. Project Manager
PharmEng Technology
Board Young Professionals Representative (Non-voting)
Contact
Term: 2018 – 2020 (Second term)

ISPE is governed by an elected board of directors. The board is composed of fifteen elected members and the CEO & President, who serves as a non-voting ex-officio member. Directors are elected to a two-year term and can serve up to two terms consecutively. All terms commence at Annual Meeting. The officer positions are Chair, Vice Chair, Treasurer, Secretary, Past Chair and the President as a non-voting ex officio member. Terms for officers are one year and the Secretary is the first officer position in the typical officer succession. Each candidate for secretary is typically making a five-year commitment to serve in the roles of Secretary through Past Chair. During the September 2016 meeting of the ISPE International Board of Directors, two important modifications were incorporated into the ISPE Bylaws. The Board approved the appointment of a Director level position to the Board and the current Chair of the International Young Professionals Committee will be invited to board meetings as an ex-officio (non-voting) member as well. The main objective of these appointments was to ensure that ISPE has the appropriate diversity within the Board to execute business strategies as defined in our ISPE Strategic Plan. For additional information on the actions from the last Board meeting or access to governance actions visit the Governance Documents FAQs page.